Trial Condition(s):
Atrial Fibrillation
Study to investigate the effect of the A1 agonist capadenoson on ventricular HR in patients with persistent or permanent atrial fibrillation.
Bayer Identifier:
12679
ClinicalTrials.gov Identifier:
EudraCT Number:
EU CT Number:
Not Available
Trial Purpose
This trial has the primary goal to show that BAY68-4986 can lower the ventricular rate in patients with the indication persistent atrial fibrillation.
Inclusion Criteria
- Male and/or female (without childbearing potential) white patients - History of persistent or permanent atrial fibrillation - 18 to 75 years of age
Exclusion Criteria
- Patients with high-risk cardiovascular diseases - Stroke or myocardial infarction - Relevant pathological changes in the ECG or echocardiography - Medication affecting ventricular response in Afib
Trial Summary
Enrollment Goal
Trial Dates
Phase
Could I receive a placebo?
Products
Accepts Healthy Volunteers
Where to Participate
| Locations | |
|---|---|
Locations CardioSec Clinical Research GmbH Erfurt, Germany, 99084 | Contact Us: E-mail: [email protected] Phone: Not Available |
Trial Design
Study to investigate the effect of the A1 agonist capadenoson on ventricular HR in patients with persistent or permanent atrial fibrillation by administration of capadenoson in a dose of 4 mg once daily for five days
Trial Type:
Interventional
Intervention Type:
Drug
Trial Purpose:
Treatment
Allocation:
Non-randomized
Blinding:
Open Label
Assignment:
Single Group Assignment
Trial Arms:
1
Primary Outcome
- The effect of capadenoson (BAY68-4986) on rate control in patients with atrial fibrillationTimeframe: 1 week
Secondary Outcome
- To investigate safety and tolerability of this treatment with capadenosonTimeframe: 2 weeks
Additional Information
Copyright © Bayer
Powered by
